The U.S. Food and Drug Administration (FDA) has granted fast track designation to BerGenBio‘s bemcentinib as a treatment for elderly people ... Read more
The European Commission has approved Astellas Pharma‘s small molecule inhibitor Xospata (gilteritinib) for the treatment of relapsed or refractory acute myeloid ... Read more